Skip to main content
Download PDF
Download ePub

Serum TNFα and IL-17A levels may predict increased depressive symptoms: findings from the Shika Study cohort project in Japan

BioPsychoSocial Medicine volume 18, Article number: 20 (2024) Cite this article

Abstract

Background

Low-grade systemic inflammation may be a key player in the immune activation that has been reported for mental health deterioration. We hypothesised that elevated serum levels of inflammatory cytokines increase neuroinflammation and exacerbate depressive symptoms.

Methods

The participants were part of a cohort study for whom data was available for both 2015 and 2019. In 2015, blood samples were collected from 232 participants. Their depressive symptoms were assessed both 2015 and 2019 using the Centre for Epidemiologic Studies Depression Scale (CES-D) (n = 33). The multiplex immunoassay system (Luminex® 200) was used to measure the serum concentrations of IL-6, IL-10, IL-12, IL-17A and TNFα. Data were analysed using linear models with the level of significance considered to be p < 0.05.

Results

After controlling for age, BMI, smoking and alcohol consumption, in 2015 the serum concentrations of IL-17A and TNFα in 2015 were significantly positively associated with the CES-D scores of women (standardised β (B) = .027, p < 0.01 and B = 0.26, p < 0.01, respectively). The serum concentrations of IL-17A and TNFα of men were significantly positively associated with the CES-D scores of 2019 (B = 0.62, p = 0.02 and B = 0.59, p = 0.02, respectively).

Conclusions

In this cross-sectional study, we found a significant positive correlation between the depressive symptoms and serum TNFα and IL-17A levels of women. In addition, our longitudinal findings suggest the possibility that TNFα and IL-17A could elevate the depressive symptoms of men.

Introduction

Theories on serotonergic dysfunction and cortisol hypersecretion do not provide sufficient explanations for the nature of depression or depressive symptoms. There is now evidence that there are pathways and mechanisms by which the immune system can influence the brain and behaviour. The central nervous system (CNS) mainly affects the immune system via the neuroendocrine outflow and the autonomic nervous system. Conversely, the immune system, including inflammation, modulates the CNS. Chronic inflammation differs from normal or acute inflammation in that the body is unable to suppress the immune response, which thus results in continuous systemic low-grade inflammation. A link between inflammatory indicators and psychological or psychiatric conditions has been reported in otherwise healthy individuals with depressive symptoms and in those with clinical depression. For example, low-grade systemic inflammation has been examined in relation to clinical depression and/or depressive symptoms [1, 2]. Previous studies have shown that chronic inflammation in various peripheral organs can render the brain vulnerable [3, 4]. The authors of some review articles have suggested that the mechanism of neuroinflammation and neurodegeneration in the CNS may be linked to peripheral inflammatory signalling [5, 6]. In the clinical field, a meta-analysis of studies into major depressive disorder (MDD) concluded that two pro-inflammatory cytokines, interleukin (IL)-6 and tumour necrosis factor-alpha (TNFα), were consistently elevated in depression, while other cytokines, such as IL-1β, IL-4, IL-2, IL-8, IL-10 and interferon-gamma (INFγ), were not [7]. Other meta-analyses have suggested associations between depression and elevated levels of inflammatory markers, such as C-reactive protein (CRP), IL-6 and, to a lesser extent, IL-1 [8, 9]. While psychological stress can lead to depression and peripheral inflammation efferently through the hypothalamic–pituitary–adrenal (HPA) axis or the sympathetic pathway, peripheral inflammatory signals can activate an inflammatory response in the CNS afferently via the blood–brain barrier (BBB) or the vagus nerve and cause depression or other disorders [10]. However, the effect of peripheral inflammation on the CNS is poorly understood, although there is increasing evidence implicating neuroinflammation in the pathogenesis of depressive disorders [10, 11].

The pro- and anti-inflammatory cytokines, TNFα, IL-6, IL-17A, IL-12 and IL-10, were selected for our investigation of the effects of chronic inflammation on the CNS. TNFα is a cytokine and an adipokine that promotes insulin resistance and activates inflammatory pathways [12]. It is derived from adipose tissue and accelerates low-grade inflammation by establishing a vicious cycle between adipocytes and macrophages [13]. For this reason, measuring TNFα is essential for evaluating the health of modern people. IL-6 acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine [14]. It is a multifunctional cytokine produced by many types of cells, including immune cells, endothelial cells, fibroblasts, myocytes and adipocytes, mediating inflammatory as well as stress-induced responses [15]. In a previous study, we found a positive association between depressive symptoms and peripheral IL-6 concentration [16].　IL-12 is the major Th1-polarising factor that enhances inflammation by activating macrophages [17]. Contrarily, it can induce neuroprotective tissue adaption that prevents early neurodegeneration and sustains trophic factor release during neuroinflammation [18]. IL-12 represents an ideal candidate for neuroinflammation or neuroprotection. IL-17A is a pro-inflammatory cytokine that is mainly secreted by T-helper 17 (Th17) lymphocytes but also by other T cells, granulocytes, monocytes and natural killer (NK) cells [19]. It is involved in atopic allergic inflammation including asthma, allergic rhinitis and conjunctivitis, atopic eczema, and food allergies [20]. The relation of atopic and allergic diseases to anxiety or depression has often been reported in the relation. One reason may be due to IL-17 increasing BBB permeability in a dose-dependent manner [21]. In addition, we reported elevated levels of serum IL-17A and higher depressive symptoms [22]. IL-10 is an anti-inflammatory cytokine produced by Th2 cells that has multiple pleiotropic effects in immunoregulation and inflammation. It downregulates the expression of Th1 cytokines and can block NF-κB activity that mediates inflammation, including IL-6 production and Th17 differentiation and its responses [23].

Despite the increasing reports of associations between peripheral chronic inflammation and depression, there is a paucity of studies involving members of the general population. Although they are closely related, it is important to distinguish between clinical depression and depressive symptoms in daily life. Preventive approaches to depression have been shown to significantly reduce the incidence of MDD [7]. This study was done to clarify the association between serum levels of inflammatory indicators and depressive symptoms among a cohort of participants from the general population, by identifying the relation between the levels of peripheral cytokines and the depressive symptoms of members of the community.

Methods

Study population

The participants were part of the Shika Study cohort project for whom data was available for both 2015 and 2019; this project has been carried out in the Noto Peninsula, Ishikawa, Japan, since 2011. The project aims to identify solutions to address lifestyle diseases by investigating community members aged 40 years or more. Details of this study have previously been reported elsewhere [22]. All of the participants were literate, understood the Japanese language well and were requested not to use proxies. The study protocol was approved by the Ethics Committee at Kanazawa University (on 18 December 2013, receipt number 1491). Written informed consent was obtained from all participants.

Procedures

Blood was sampled in 2015. Demographic and questionnaire data were collected in both 2015 and 2019. Figure 1 shows the study procedure.

Fig. 1
figure 1

Flow chart showing the participant recruitment procedure

Full size image

Questionnaire

A self-administered questionnaire was distributed to participants in advance, and the completed questionnaires were collected on the day of their medical examination. The entire process was conducted paying careful attention to the protection of their privacy. The questionnaire included items relating to demographic characteristics (age, sex, height, weight, present health status, diseases, medication, etc.) and lifestyle characteristics (smoking status, alcohol consumption and if they lived alone). Depressive symptoms were assessed using the Japanese version of the Centre for Epidemiologic Studies Depression Scale (CES-D) [24, 25]. Of the 492 persons initially recruited in 2015, 409 participants (200 males, mean age ± standard deviation (SD) = 59.1 ± 11.5; 208 females, mean age ± SD 61.1 ± 12.9; 1 unknown) out of 492 gave their consent to participate in this study in 2015. In 2019, the same procedure was carried out, with 96 men (mean age ± SD = 64.8 ± 10.28) and 116 women (mean age ± SD = 61.2 ± 10.70) from the original cohort consenting to participate.

Blood collection

Fasting blood sampling was done between 0800 and 1200, with blood taken from the forearm vein was collected in heparinised and serum-separator vacutainer tubes, after which sera was separated via centrifugation. The serum samples were delivered to Kanazawa University through a commercial laboratory (SRL Kanazawa Laboratory, Kanazawa, Japan). The sera were frozen and stored at − 30°C until the assays were performed two months after sampling.

Assays for inflammation-associated factors

The serum samples were tested for TNFα, IL-6, IL-10, IL-12p70 and IL-17A using a multiplex human immunoassay kit (Luminex® 200TM) with the human high sensitivity T cell panel (Merck Japan, Tokyo, Japan).

Statistical analysis

The Japanese version of IBM SPSS Statistics 29 (IBM Japan, Tokyo, Japan) was used for data analysis. An unpaired t-test was used for comparisons between two groups, Pearson’s correlation test was used to explore correlations between two groups, following, a linear regression analysis done to adjust for confounders. The level of significance was considered to be p < 0.05.

Results

Table 1 presents the participants’ characteristics. Significant differences between men and women were observed for BMI and serum IL-17A concentration, with both variables being significantly higher in men than women (t-test: t = 3.86, p < 0.0005 and t = 2.75, p = 0.006, respectively). There were no significant differences between the sexes for other variables, including smoking, alcohol consumption, and if they lived alone.

Table 1 Demographic and clinical characteristics of participants
Full size table

In 2015, significant positive correlations were observed for women between the CES-D scores and the concentrations of the serum cytokines TNFα and IL-17A were observed among women (simple correlation: r = 0.25, p = 0.006 and r = 0.26, p = 0.003, respectively) (Fig. 2). In 2019, a significant positive correlation was observed for men between the CES-D scores and the concentration of the serum cytokine TNFα (simple correlation: r = 0.63, p = 0.007) (Fig. 3). There were no significant correlations between the CES-D score and the serum concentration of any of the other cytokines in 2015 or 2019. For the CES-D scores in 2019, when the cutoff for IL-17A concentration was set at 3.35 pg/mL, the serum IL-17A level of the higher group (mean ± S.D.: 16.0 ± 59.12, n = 9) showed significantly higher CES-D scores in 2019 in comparison with those of the lower IL-17A group (6.3 ± 9.12, n = 8) (t-test: t = 2.63, p = 0.019). After adjusting for confounders such as age, BMI, smoking, alcohol consumption, and if the participant lived alone, regression analyses were performed to explore if there were links between depressive symptoms and each subject cytokine. As shown in Table 2, in 2015, IL-17A was a significant, positively related factor that could explain the CES-D scores of women in all of the models (Model 1: F = 8.82 (1, 109), standardised β (B) = 0.26, p = 0.004; Model 2: F = 3.63 (3, 117), B = 0.27, p = 0.003; Model 3: F = 2.28 (5, 115), B = 0.27, p = 0.003; Model 4: F = 1.85 (6, 112), B = 0.27, p = 0.003). TNFα was a significant, positively related factor in 2015 that could explain the CES-D scores of women in all of the models (Model 1: F = 7.67 (1, 109), B = 0.25, p = 0.007; Model 2: F = 3.20 (3, 117), B = 0.26, p = 0.005; Model 3: F = 2.00 (5, 115), B = 0.26, p = 0.006; Model 4: F = 1.62 (6, 112), B = 0.26, p = 0.007) (Table 2). Table 3 shows that IL-17A in 2019 was a significant, positive factor for predicting the CES-D scores of men in 2019 (Model 1: F = 6.90 (1, 15), B = 0.56, p = 0.019; Model 2: F = 2.50 (3, 13), B = 0.57, p = 0.023; Model 3: F = 2.15 (5, 11), B = 0.62, p = 0.017). TNFα was also a significant, positive factor for predicting the CES-D scores of men in 2019 (Model 1: F = 9.69 (1, 15), B = 0.63, p = 0.007; Model 2: F = 3.12 (3, 13), B = 0.61, p = 0.013; Model 3: F = 1.90 (5, 11), B = 0.59, p = 0.024) (Table 3).

Fig. 2
figure 2

Correlations between depressive symptoms and serum cytokine concentrations in 2015. In 2015, significant positive correlations between CES-D scores and serum concentrations of the cytokines TNFα and IL-17A were observed in women. IL-6, IL-10, IL-12 and IL-17 concentrations were base 10 log-transformed. CES-D: the Centre for Epidemiologic Studies Depression Scale

Full size image
Fig. 3
figure 3

Correlations between depressive symptoms in 2019 and serum cytokine concentrations in 2015. In 2019, a significant, positive correlation between the CES-D scores and serum concentrations of the cytokine TNFα was observed in men. As to the CES-D scores of men in 2019, when IL-17A concentrations were divided into higher and lower groups with a cutoff at 3.35 pg/mL, the serum IL-17A level of the higher group showed significantly increased CES-D scores in 2019 in comparison with that of the lower IL-17A group (t-test: t = 2.63, p = 0.019). IL-6, IL-10, IL-12 and IL-17 concentrations were base 10 log-transformed. CES-D: the Centre for Epidemiologic Studies Depression Scale

Full size image
Table 2 Linear models that explain depressive symptoms in 2015
Full size table
Table 3 Linear models that predict depressive symptoms in 2019
Full size table

Discussion

In the current study, we investigated the association between peripheral cytokine levels and the depressive symptoms of community dwellers aged 40 years and older, both cross-sectionally and longitudinally. Among women, we identified significant positive associations between depressive symptoms and their serum of TNFα and IL-17A levels. We also found that elevated TNFα and IL-17A levels were significantly associated with increased depressive symptoms among men four years after the first examination.

Depression is a complex disease with a multifactorial background [26]. Based on studies conducted to date, it is not possible to clearly define the causes and mechanisms of depression [26, 27]. However, several theories have been put forward that have attempted to explain its underlying causes, including the monoamine hypothesis, a neurotrophic theory, dysfunction of the HPA axis, and neurodegenerative and inflammatory alterations. Depression is a major public health issue and is projected to become the leading cause of disability worldwide by 2030 [28]. Although clinical depression and depressive symptoms in daily life should be distinguished, they are closely related. Preventive approaches to depression have been found to significantly reduce the incidence of MDD [28]. In the present study, we investigated the effects of low-grade systemic inflammation on depressive symptoms. Our work was informed by the neuroinflammatory theory of depression, because the inflammatory response system activates the HPA axis, leading to the production of corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH). An increase in the turnover of serotonin and catecholamines has also been reported [29].

IL-17A

IL-17A is a pro-inflammatory cytokine that was the first member of the IL-17 family to be identified. The overproduction of IL-17A promotes hyperinflammation and tissue damage in a variety of diseases [30]. The role of IL-17 in the pathogenesis and progression of depression is a relatively new area of research that has recently been gaining emphasis. Patients with MDD have been found to exhibit increased levels of circulating cytokines, such as IL-1b, IL-6 and TNFα, which play important roles in Th17 differentiation and effector action [31, 32]. IL-17 stimulates the production of various inflammatory mediators, such as intercellular adhesion molecule 1 (ICAM-1), prostaglandin E2 (PGE2), matrix metalloproteinases (MMPs) and antimicrobial peptides, that are involved in tissue damage [33]. The induction and release of such mediators also appears to amplify IL-17 production via a positive feedback loop, thus propagating inflammatory damage [34]. Furthermore, patients with MDD who responded to treatment with antidepressants showed a reduction in plasma IL-17 levels [31]. A potential limitation of the present study is differences in the composition of fluids in the CNS and the peripheral serum, particularly because the BBB partitions the brain from circulating blood and because cytokines are relatively large molecules that cannot pass freely across the BBB. However, some studies have identified various means by which inflammatory signals may be transmitted from the periphery to the brain. Increased circulation of inflammatory factors could potentially increase the permeability of the BBB, allowing cytokines to cross, particularly through the choroid plexus and circumventricular organs [35]. Furthermore, cytokine signals could be transmitted via afferent vagus nerve fibres, triggering the release of second messengers in the brain such as prostaglandins and nitric oxide [35]. Alternatively, cytokines could cross the BBB via active transport [35]. Although little is currently known about the mechanism by which IL-17A infiltrates the brain and its mode of action, i.e. whether IL-17A acts directly in the brain or indirectly by some cascades across the BBB, some recent reports have indicated that there may be a relation between peripheral IL-17 concentration and depression. For example, patients with first-episode depressive disorder showed higher serum levels of IL-17 [36]. The IL-17 serum concentrations of patients with MDD were significantly higher than those seen in a control group [37]. Preclinical studies on animal models have shown that IL-17 induced by stress promotes depression-like behaviours [38, 39]. IL-17 is unique in that IL-17A has been reported to access the brain by disrupting the integrity of the BBB and its receptors [40], IL-17RA and IL-17RC, are richly expressed in the CNS [41]. In addition, a recent study of mice indicated that IL-17 promotes synaptic dysfunction and that neutralization of IL-17 prevents synaptic dysfunction [42]. This report also reported that anti-IL-17 treatment using monoclonal antibody appeared to be effective against such dysfunction [42].

In our present cross-sectional study of people living in the community, serum IL-17A concentrations and depressive symptoms showed a significant, positive association among women. Furthermore, our longitudinal study indicated that elevated serum IL-17A levels in men predicted higher depressive symptoms four years later. The above-mentioned mechanism of IL-17 in the CNS supports our results, although the reasons for these sex based differences are currently unclear.

TNFα

TNFα was also shown to be related to an elevation of depressive symptoms in the current study. TNFα is a pro-inflammatory cytokine that is secreted by many types of cells and tissues. It has recently attracted attention in relation to obesity and inflammation [43, 44]. In relation to depression, it has been established that TNFα, as do IL-1 and IL-6, induces not only symptoms of physical sickness but also major depressive disorders in physically ill patients with no previous history of mental disorders [45]. In addition, studies using animal models have indicated that TNFα inhibition improved depression-like behaviour [46, 47].

The effects of TNFα on depression may be due to its activation of the HPA axis and a subsequent reduction in serotonin (5-HT) metabolism in addition to the vulnerability of the BBB to the inflammatory function of TNFα. Several findings have been made that indicate TNFα has an influence on serotonin metabolism as well as on the HPA axis. It has been suggested that TNFα activates the HPA axis during inflammatory reactions [48]. Another study suggested that TNFα and the HPA system have a mutual influence on depressed patients without inflammatory diseases [49]. Furthermore, TNFα was shown to elicit considerable decreases in 5-HT transporter function [50].

Although the precise mechanism is unknown, the present study showed associations between TNFα and the degree of depressive symptoms, cross-sectionally in women and longitudinally in men.

IL-10

There have been contradictory findings in relation to associations between serum the IL-10 level and depression. A case–control study involving patients with MDD and individuals without depression showed that the patients with MDD exhibited higher levels of plasma IL-10 [31]. However, in the same study, patients who received antidepressant treatment exhibited elevated plasma IL-10 concentrations [31]. In a mouse model of depression, microglial but not peripheral blood IL-10 levels were reduced in learned helplessness mice; administration of IL-10 improved procognitive actions in learned helplessness mice or mice with cognitive impairments [51]. These contradictory findings in relation to IL-10 could be due to its pleiotropic effects of IL-10. It is an anti-inflammatory cytokine produced by Treg cells and plays an important role in preventing inflammation. However, it can activate Th2 cells and B cells [52] while also inhibiting to macrophages and Th1 cells and suppressing Th17 cell-mediated inflammation; thus, IL-10 can be both immunostimulatory as well as immunosuppressive.

In the current study, there were no significant associations between the serum IL-10 level and depressive symptoms.

IL-6

Similar to TNFα, IL-6 has long been investigated in relation to the pathophysiology of depression. However, previous studies have reported contradictory findings with regard to links between elevated IL-6 levels in patients with depressive symptoms or those with MDD. This may have been due to confounders, the participants’ characteristics, or to heterogeneity among patients with MDD. For example, the IL-6 levels of patients with melancholic depression were significantly increased compared with those of healthy participants, while there was no significant difference when compared with patients with atypical depression [53]. This finding was consistent with that of another study that indicated that IL-6 levels are correlated with different subtypes of MDD [54]. A large cohort study among British civil servants (a general population or with MDD not specified) showed that higher serum levels of IL-6 at baseline were associated with subsequent cognitive symptoms of depression in both sexes at follow-up [55].

In the present study, carried out among community members aged 40 years of age or older in an urban area of Japan, there were no correlations between depressive symptoms and serum IL-6 levels, either cross-sectionally or longitudinally. However, a cross-sectional study that we carried out involving female nursing workers indicated a significant positive correlation between depressive symptoms and serum IL-6 levels [16]. The reason for these differences is unclear. It may be due to latent confounders or type-1 errors. Alternatively, it might be due to differences in the characteristics of the study cohort: the average CES-D score of participants in the present study was 10.1 in 2015, whereas in our earlier study it was 14.8 [16].

IL-12

IL-12 is a pro-inflammatory cytokine that influences cellular immunity by promoting Th1 response. It enhances the cytotoxic activity of NK cells and facilitates cytotoxic T lymphocyte generation [56]. There are fewer reports on the relation between IL-12 and depression than there are for the other cytokines investigated in the present study. However, some studies have found elevated serum IL-12 levels in patients of MDD and rat depression models. For example, a recent study showed an increased serum IL‐12 level in patients with MDD in comparison with controls and a positive correlation between the serum IL‐12 levels and Hamilton Depression Rating Scale scores of patients with MDD [57]. Contrarily, an animal experiment revealed a protective effect of IL-12 against neuroinflammation [18]. A review article noted that the IL-12 serum/plasma level may be clinically valuable as part of a complex diagnostic approach to depression, although this must be carefully interpreted, taking into account confounders that can alter the same pro-inflammatory pathways and overlap with each other [58]. In the current study we found no significant associations between the concentration of IL-12 and depressive symptoms, possibly due to multifunctional effects of the IL-12.

Pathways to the central nervous system

In discussion of peripheral inflammatory markers and brain reaction or depression, signals of which cytokines cross the BBB should be considered, as mentioned in the IL-17A section above. There are two types of pathways by which peripheral immune signals are transmitted to the brain, BBB-dependent and BBB-independent [59]. The BBB-independent pathways use the vagus nerve, which bypasses the BBB, whereas there are various BBB-dependent pathways, including vulnerability of the BBB itself, humoral pathways, cellular pathways including active transport, activation of NF-κB signalling and through adhesion molecules [35]. Although it was recently discovered that microglia play a role in BBB permeability during systemic inflammation [60], the precise factor remains unclear. Some inflammatory materials can evoke inflammation of the central nervous system, which can induce depression. A study of depression found that increased IL-6 levels were correlated with dysconnectivity of a brain functional network [61]. However, further research is required to clarify the pathway.

Effects of disease and medication on immune indicators

It is essential to consider the effects of diseases and drugs on immunity. In the 2015 survey, one woman was diagnosed with rheumatoid arthritis (RA). One man and one woman had atopic dermatitis (AD). RA and AD are IL-6-related diseases that may also related to the production of other cytokines. In our statistical analysis, when we excluded the participants with RA or AD one by one, the levels of significance presented in Table 2 did not change.

It may also be necessary to exclude participants diagnosed with MDD. In our current study, we surveyed members of a community population who had not been previously hospitalised or had problems with absenteeism from work. One woman self-reported that she suffered from depression: her CES-D score was 44, the highest among the participants in 2015. The woman took an antidepressant as a sleeping aid (trazodone) and anxiolytics (alprazolam, diazepam). We found no reports regarding any relation between the above-mentioned medicines and IL-17 or TNFα [62, 63, 64, 65]. Because diazepam and alprazolam generally have contradictory effects on immune response [17], their simultaneous administration has no or very little effect on immune functions. Furthermore, the use of antidepressants to treat depression could decrease the peripheral IL-17A level [31]. In addition, this person engaged in regular physical activities during her leisure time, suggesting that her depressive status was not so severe that it affected her behaviour. Patients with MDD generally cannot continue physical activities due to loss of interest or motivation. Judging from her medication and lifestyle, the participant would not be diagnosed as having MDD: her symptoms could have been menopausal symptoms, with unidentified complaints and an accompanying sleep disorder. Her data was included this individual in our analysis. If it had been excluded, the levels of significance presented in Table 2 would have remained the same for IL-17A but not for TNFα.

Prevention and treatment

Given that low-grade inflammation partially drives depressive symptoms, anti-inflammatory agents or non-pharmacological interventions in daily life may be beneficial. As mentioned at the last prat of the IL-17A section, treatment using monoclonal antibody may be useful [42]. A meta-analysis for anti-inflammatory treatment reported that anti-TNF antibodies (such as infliximab), non-steroidal anti-inflammatory drugs (NSAIDs) and omega-3 fatty acids improved depressive symptoms [66]. Other review suggested non-pharmacological interventions such as physical exercise, probiotics, omega-3 fatty acids [67].

Limitations

First, a limitation of this study is the small sample size of patients evaluated using CES-D in 2019. Second, the different results by sex cannot be explained.

Conclusions

We found that serum of IL-17A and TNFα levels were significantly, positively associated with the depressive symptoms of women, while in men they predicted depressive symptoms four years later. In the context of inflammation, IL-17A and TNFα can access the CNS and hence influence the brain neurocircuits that regulate mood, motor activity, motivation, etc. Our results provide insights that a lifestyle that protects against the generation of inflammatory responses may, at least partially, be related to preventing depression and to maintaining a healthy mental status.

Availability of data and materials

The authors do not have permission to share data.

References

  1. Rawdin BJ, Mellon SH, Dhabhar FS, Epel ES, Puterman E, Su Y, Burke HM, Reus VI, Rosser R, Hamilton SP, et al. Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun. 2013;31:143–52.

    Article  CAS  PubMed  Google Scholar 

  2. Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry. 2009;22:75–83.

    Article  PubMed  Google Scholar 

  3. Mongan D, Raj Susai S, Föcking M, Byrne JF, Zammit S, Cannon M, Cotter DR. Associations between plasma inflammatory markers and psychotic disorder, depressive disorder and generalised anxiety disorder in early adulthood: A nested case-control study. Brain Behav Immun. 2023;111:90–100.

    Article  CAS  PubMed  Google Scholar 

  4. Riazi K, Galic MA, Kentner AC, Reid AY, Sharkey KA, Pittman QJ. Microglia-dependent alteration of glutamatergic synaptic transmission and plasticity in the hippocampus during peripheral inflammation. J Neurosci. 2015;35:4942–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Abautret-Daly Á, Dempsey E, Parra-Blanco A, Medina C, Harkin A. Gut-brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease. Acta Neuropsychiatr. 2018;30:275–96.

    Article  PubMed  Google Scholar 

  6. Réus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, Kapczinski F, Quevedo J. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 2015;300:141–54.

    Article  PubMed  Google Scholar 

  7. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57.

    Article  CAS  PubMed  Google Scholar 

  8. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.

    Article  CAS  PubMed  Google Scholar 

  9. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002;25:154–9.

    Article  CAS  PubMed  Google Scholar 

  10. Sun Y, Koyama Y, Shimada S. Inflammation from peripheral organs to the brain: how does systemic inflammation cause neuroinflammation? Front Aging Neurosci. 2022;14:903455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160:1554–65.

    Article  PubMed  Google Scholar 

  12. Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor. Nat Metab. 2021;3:1302–12.

    Article  CAS  PubMed  Google Scholar 

  13. Itoh M, Suganami T, Hachiya R, Ogawa Y. Adipose tissue remodeling as homeostatic inflammation. Int J Inflam. 2011;2011:720926.

    PubMed  PubMed Central  Google Scholar 

  14. Nara H, Watanabe R. Anti-inflammatory effect of muscle-derived interleukin-6 and its involvement in lipid metabolism. Int J Mol Sci. 2021;22(18):9889.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Fernández-Real J-M, Ricart W. 13 - chronic inflammatory hypothesis in the metabolic syndrome. In: Serrano Ríos M, Caro JF, Carraro R, Gutiérrez Fuentes JA, editors. The metabolic syndrome at the beginning of the XXI century. Madrid: Elsevier España; 2005. p. 217–31.

    Chapter  Google Scholar 

  16. Tsuboi H, Sakakibara H, Tatsumi A, Yamakawa-Kobayashi K, Matsunaga M, Kaneko H, Shimoi K. Serum IL-6 levels and oxidation rate of LDL cholesterol were related to depressive symptoms independent of omega-3 fatty acids among female hospital and nursing home workers in Japan. J Affect Disord. 2019;249:385–93.

    Article  CAS  PubMed  Google Scholar 

  17. Athie-Morales V, Smits HH, Cantrell DA, Hilkens CM. Sustained IL-12 signaling is required for Th1 development. J Immunol. 2004;172:61–9.

    Article  CAS  PubMed  Google Scholar 

  18. Andreadou M, Ingelfinger F, De Feo D, Cramer TLM, Tuzlak S, Friebel E, Schreiner B, Eede P, Schneeberger S, Geesdorf M, et al. IL-12 sensing in neurons induces neuroprotective CNS tissue adaptation and attenuates neuroinflammation in mice. Nat Neurosci. 2023;26:1701–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol. 2000;2015(69):142–59.

    Google Scholar 

  20. Hofmann MA, Fluhr JW, Ruwwe-Glösenkamp C, Stevanovic K, Bergmann KC, Zuberbier T. Role of IL-17 in atopy-A systematic review. Clin Transl Allergy. 2021;11:e12047.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lécuyer MA, Kebir H, Prat A. Glial influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta. 2016;1862:472–82.

    Article  PubMed  Google Scholar 

  22. Tsuboi H, Sakakibara H, Minamida Y, Tsujiguchi H, Matsunaga M, Hara A, Nakamura H. Elevated levels of serum IL-17A in community-dwelling women with higher depressive symptoms. Behavioral sciences (Basel, Switzerland). 2018;8:102.

    PubMed  Google Scholar 

  23. Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. MedComm. 2020;2021(2):618–53.

    Google Scholar 

  24. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.

    Article  Google Scholar 

  25. Shima S, Shikano TTK, Asai M.  New self-rating scale for depression. Clin Psychiatry. 1985;27:717–23.

    Google Scholar 

  26. Malhi GS, Mann JJ. Depression. The Lancet. 2018;392:2299–312.

    Article  Google Scholar 

  27. Mrozek W, Socha J, Sidorowicz K, Skrok A, Syrytczyk A, Piątkowska-Chmiel I, Herbet M. Pathogenesis and treatment of depression: role of diet in prevention and therapy. Nutrition. 2023;115:112143.

    Article  PubMed  Google Scholar 

  28. Ebert DD, Cuijpers P. It is time to invest in the prevention of depression. JAMA Netw Open. 2018;1:e180335–e180335.

    Article  PubMed  Google Scholar 

  29. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol. 1999;461:25–46.

    Article  CAS  PubMed  Google Scholar 

  30. Xu B, Chen J, Fu J, Yang R, Yang B, Huo D, Tan C, Chen H, Wang X. Meningitic escherichia coli-Induced interleukin-17A facilitates blood-brain barrier disruption via inhibiting proteinase 3/protease-activated receptor 2 axis. Front Cell Neurosci. 2022;16:814867.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Syed SA, Beurel E, Loewenstein DA, Lowell JA, Craighead WE, Dunlop BW, Mayberg HS, Dhabhar F, Dietrich WD, Keane RW, et al. Defective inflammatory pathways in never-treated depressed patients are associated with poor treatment response. Neuron. 2018;99:914–924.e913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Slyepchenko A, Maes M, Köhler CA, Anderson G, Quevedo J, Alves GS, Berk M, Fernandes BS, Carvalho AF. T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model. Neurosci Biobehav Rev. 2016;64:83–100.

    Article  CAS  PubMed  Google Scholar 

  33. Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2012;122:487–511.

    Article  CAS  PubMed  Google Scholar 

  34. Benedetti G, Miossec P. Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur J Immunol. 2014;44:339–47.

    Article  CAS  PubMed  Google Scholar 

  35. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130:226–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Mao L, Ren X, Wang X, Tian F. Associations between autoimmunity and depression: serum IL-6 and IL-17 have directly impact on the HAMD scores in patients with first-episode depressive disorder. J Immunol Res. 2022;2022:6724881.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Davami MH, Baharlou R, Ahmadi Vasmehjani A, Ghanizadeh A, Keshtkar M, Dezhkam I, Atashzar MR. Elevated IL-17 and TGF-beta serum levels: a positive correlation between T-helper 17 cell-related pro-inflammatory responses with major depressive disorder. Basic Clin Neurosci. 2016;7:137–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Kim J, Suh Y-H, Chang K-A. Interleukin-17 induced by cumulative mild stress promoted depression-like behaviors in young adult mice. Mol Brain. 2021;14:11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Tallerova AV, Kovalenko LP, Durnev AD, Seredenin SB. Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice. Eksp Klin Farmakol. 2011;74:3–5.

    CAS  PubMed  Google Scholar 

  40. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Sarma JD, Ciric B, Marek R, Sadhukhan S, Caruso ML, Shafagh J, Fitzgerald DC, Shindler KS, Rostami AM. Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2009;6:14.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Brigas HC, Ribeiro M, Coelho JE, Gomes R, Gomez-Murcia V, Carvalho K, Faivre E, Costa-Pereira S, Darrigues J, de Almeida AA, et al. IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer’s disease. Cell Rep. 2021;36:109574.

    Article  CAS  PubMed  Google Scholar 

  43. Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa A, Gorecka D, Pyrzak B, Demkow U. Proinflammatory cytokines Il-6 and TNF-α and the development of inflammation in obese subjects. Eur J Med Res. 2010;15(Suppl 2):120–2.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Suganami T, Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol. 2010;88:33–9.

    Article  CAS  PubMed  Google Scholar 

  45. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Şahin TD, Karson A, Balcı F, Yazır Y, Bayramgürler D, Utkan T. TNF-alpha inhibition prevents cognitive decline and maintains hippocampal BDNF levels in the unpredictable chronic mild stress rat model of depression. Behav Brain Res. 2015;292:233–40.

    Article  PubMed  Google Scholar 

  47. Krügel U, Fischer J, Radicke S, Sack U, Himmerich H. Antidepressant effects of TNF-α blockade in an animal model of depression. J Psychiatr Res. 2013;47:611–6.

    Article  PubMed  Google Scholar 

  48. Dunn AJ. Cytokine activation of the HPA axis. Ann N Y Acad Sci. 2000;917:608–17.

    Article  CAS  PubMed  Google Scholar 

  49. Himmerich H, Binder EB, Künzel HE, Schuld A, Lucae S, Uhr M, Pollmächer T, Holsboer F, Ising M. Successful antidepressant therapy restores the disturbed interplay between TNF-α system and HPA axis. Biol Psychiat. 2006;60:882–8.

    Article  CAS  PubMed  Google Scholar 

  50. Foley KF, Pantano C, Ciolino A, Mawe GM. IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in Caco2 cells. Am J Physiol Gastrointest Liver Physiol. 2007;292:G779–784.

    Article  CAS  PubMed  Google Scholar 

  51. Worthen RJ, Garzon Zighelboim SS, Torres Jaramillo CS, Beurel E. Anti-inflammatory IL-10 administration rescues depression-associated learning and memory deficits in mice. J Neuroinflammation. 2020;17:246.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Laouini D, Alenius H, Bryce P, Oettgen H, Tsitsikov E, Geha RS. IL-10 is critical for Th2 responses in a murine model of allergic dermatitis. J Clin Invest. 2003;112:1058–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Karlović D, Serretti A, Vrkić N, Martinac M, Marčinko D. Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res. 2012;198:74–80.

    Article  PubMed  Google Scholar 

  54. Spanemberg L, Caldieraro MA, Vares EA, Wollenhaupt-Aguiar B, Kauer-Sant’Anna M, Kawamoto SY, Galvão E, Parker G, Fleck MP. Biological differences between melancholic and nonmelancholic depression subtyped by the CORE measure. Neuropsychiatr Dis Treat. 2014;10:1523–31.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Gimeno D, Kivimäki M, Brunner EJ, Elovainio M, De Vogli R, Steptoe A, Kumari M, Lowe GD, Rumley A, Marmot MG, Ferrie JE. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2009;39:413–23.

    Article  CAS  PubMed  Google Scholar 

  56. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251–76.

    Article  CAS  PubMed  Google Scholar 

  57. Nahar Z, Sal-Sabil N, Sohan M, Qusar MS, Islam MR. Higher serum interleukin-12 levels are associated with the pathophysiology of major depressive disorder: a case-control study results. Health Sci Rep. 2023;6:e1005.

    Article  PubMed  Google Scholar 

  58. Harsanyi S, Kupcova I, Danisovic L, Klein M. Selected biomarkers of depression: what are the effects of cytokines and inflammation? Int J Mol Sci. 2022;24(1):578.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Quan N. Immune-to-brain signaling: how important are the blood-brain barrier-independent pathways? Mol Neurobiol. 2008;37:142–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Haruwaka K, Ikegami A, Tachibana Y, Ohno N, Konishi H, Hashimoto A, Matsumoto M, Kato D, Ono R, Kiyama H, et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun. 2019;10:5816.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Aruldass AR, Kitzbichler MG, Morgan SE, Lim S, Lynall ME, Turner L, Vertes P, Cavanagh J, Cowen P, Pariante CM, et al. Dysconnectivity of a brain functional network was associated with blood inflammatory markers in depression. Brain Behav Immun. 2021;98:299–309.

    Article  CAS  PubMed  Google Scholar 

  62. Baumeister D, Ciufolini S, Mondelli V. Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology. 2016;233:1575–89.

    Article  CAS  PubMed  Google Scholar 

  63. Daniele S, Zappelli E, Martini C. Trazodone regulates neurotrophic/growth factors, mitogen-activated protein kinases and lactate release in human primary astrocytes. J Neuroinflammation. 2015;12:225.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Wei M, Li L, Meng R, Fan Y, Liu Y, Tao L, Liu X, Wu C. Suppressive effect of diazepam on IFN-gamma production by human T cells. Int Immunopharmacol. 2010;10:267–71.

    Article  CAS  PubMed  Google Scholar 

  65. Covelli V, Passeri ME, Leogrande D, Jirillo E, Amati L. Drug targets in stress-related disorders. Curr Med Chem. 2005;12:1801–9.

    Article  CAS  PubMed  Google Scholar 

  66. Simon MS, Arteaga-Henríquez G, Fouad Algendy A, Siepmann T, Illigens BMW. Anti-inflammatory treatment efficacy in major depressive disorder: a systematic review of meta-analyses. Neuropsychiatr Dis Treat. 2023;19:1–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Suneson K, Lindahl J, Chamli Hårsmar S, Söderberg G, Lindqvist D. Inflammatory depression-mechanisms and non-pharmacological interventions. Int J Mol Sci. 2021;22(4):1640.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank the clinical staff at health check-up locations for their assistance with this project. Moreover, we are grateful to all the study participants who generously gave their time and collaborated with our study.

Funding

This research was supported by Grant-in-Aid for Scientific Research (C) 16K01787 Ministry of Education, Culture, Sports, Science and Technology, Japan.

Author information

Authors and Affiliations

  1. Graduate School of Human Sciences, The University of Shiga Prefecture, 2500 Hassaka-Cho, Hikone, 522-8533, Japan

    Hirohito Tsuboi

  2. Research Group of Psychosomatic Medicine, Faculty of Pharmacy, Pharmaceutical and Health Sciences, Kanazawa University, 1 Kakuma-Machi, Kanazawa, 920-1192, Japan

    Hirohito Tsuboi & Yuuki Minamida-Urata

  3. Department of Hygiene and Public Health, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takara-Machi, Kanazawa, 920-8641, Japan

    Hirohito Tsuboi, Hiromasa Tsujiguchi, Akinori Hara, Keita Suzuki, Masaharu Nakamura, Chie Takazawa, Jiaye Zhao, Aki Shibata, Aya Ogawa & Hiroyuki Nakamura

  4. Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada-ku, Kobe, 657-8501, Japan

    Hiroyuki Sakakibara

  5. Department of Bioinformatics and Genomics, Graduate School of Advanced Preventive Medical Sciences, Kanazawa University, 13-1 Takara-Machi, Kanazawa, 920-8640, Japan

    Atsushi Tajima

  6. Innovative Clinical Research Center, Kanazawa University, 13-1 Takara-Machi, Kanazawa, Japan

    Sakae Miyagi

  7. Department of Biomedical Data Science, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, 470-1192, Japan

    Takayuki Kannon

  8. Department of Nursing, Faculty of Health Sciences, Komatsu University, 10-10 Doihara-Machi, Komatsu, 923-0921, Japan

    Yukari Shimizu

  9. Department of Geriatric Dentistry, Ohu University School of Dentistry, 31-1 Misumido, Koriyama, 963-8611, Japan

    Fumihiko Suzuki

  10. Department of Public Health, Faculty of Veterinary Medicine, Okayama University of Science, 1-3 Ikoinooka, Imabari, 794-8555, Japan

    Yasuhiro Kambayashi

  11. Division of Diabetes Endocrinology and Metabolism, Yachiyo Medical Center, Tokyo Women’s Medical University, 477-96 Owada-Shinden, Yachiyo, Japan

    Tadashi Konoshita

Authors
  1. Hirohito Tsuboi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Sakakibara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuuki Minamida-Urata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiromasa Tsujiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akinori Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keita Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sakae Miyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masaharu Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chie Takazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takayuki Kannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jiaye Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yukari Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Aki Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Aya Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Fumihiko Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Yasuhiro Kambayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Tadashi Konoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Atsushi Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Hiroyuki Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HT (Hirohito Tsuboi) carried out the psychological assessment of the study, the data analyses, the cytokine analysis, and drafted the manuscript. HS and YMU contributed to the detection of cytokines. HT (Hiromasa Tsujiguchi) and AH managed the participants. KS, MS, NM, CT, TK (Tadashi Konoshita), JZ, YS, AS, AO, FS, YK, TK (Takayuki Kannon) and AT contributed to the data collection. HN conducted the whole cohort study.

Corresponding author

Correspondence to Hirohito Tsuboi.

Ethics declarations

Ethics approval and consent to participate

This study was reviewed and approved by the Ethics Committee at Kanazawa University (on 18 December 2013, receipt number 1491). All participants provided written informed consent prior to study participation.

Consent for publication

All authors have given consent for publication.

Competing interests

The authors declare that there are no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsuboi, H., Sakakibara, H., Minamida-Urata, Y. et al. Serum TNFα and IL-17A levels may predict increased depressive symptoms: findings from the Shika Study cohort project in Japan. BioPsychoSocial Med 18, 20 (2024). https://doi.org/10.1186/s13030-024-00317-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13030-024-00317-5

Keywords

BioPsychoSocial Medicine

ISSN: 1751-0759

Contact us